Santen reports Phase I/II safety data for wet AMD candidate

Santen Pharmaceutical Co. Ltd. (Tokyo:4536) reported data from a Phase I/II trial in 12 patients with wet age-related macular degeneration (AMD) refractory to VEGF inhibitors showing that single intravitreal injections of DE-122 (carotuximab, Ophthalmic TRC105) were well tolerated with no serious adverse events reported. Data were presented at the Angiogenesis, Exudation and Degeneration meeting in Miami.

The open-label, dose-escalation, U.S. trial is evaluating safety and the change from baseline to day 90 in central subfield thickness, macular volume and best corrected visual acuity (BCVA)...